Modified Vaccinia Virus Attenuation via Gene Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of attenuated viruses for therapeutic and diagnostic purposes is hindered by the difficulty in predicting the effects of combinations of genetic modifications, which often result in reduced viral functions necessary for replication, and the challenge of generating packaging cell lines due to toxic viral proteins.
Innovation Solution
The creation of recombinant vaccinia viruses with modified genes, such as the thymidine kinase (TK) and hemagglutinin (HA) genes, and the insertion of heterologous nucleic acids to encode therapeutic or diagnostic proteins, linked to specific promoters like vaccinia early, intermediate, or late promoters, to achieve desired levels of attenuation and pathogenicity modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If repeated passage through cell lines and/or animals is used to attenuate viruses, then pathogenicity is reduced, but the process requires extensive testing and time
Solution Approach 1:
The patent applies preliminary action by pre-identifying specific viral genes (such as TK, HA, and other non-essential genes) that can be targeted for mutation to achieve attenuation. Instead of performing repeated passages and extensive testing, the invention provides a predetermined set of genetic targets that, when modified, directly produce attenuated viral strains with reduced pathogenicity, significantly shortening the development timeline.
Solution Approach 2:
The patent employs parameter changes by modifying specific genetic parameters (gene sequences) of the virus to achieve attenuation. By changing the nucleic acid sequence of identified non-essential genes through targeted mutations, the invention transforms the viral properties to reduce pathogenicity while preserving replication competence, eliminating the need for time-consuming iterative passages.
2Object-affected harmful factors
If additional genes are mutated or combinations of modifications are made to increase attenuation, then pathogenicity is reduced, but predicting the effects becomes difficult and requires extensive testing
Solution Approach 1:
The patent applies segmentation by dividing the viral genome into specific functional segments and identifying which segments (genes) are non-essential for pathogenicity but can be modified without compromising viral replication. By segmenting the attenuation strategy into targeted mutations of specific genes (TK, HA, etc.), the invention simplifies the complexity of predicting combined modification effects, as each gene's function and impact are independently understood.
Solution Approach 2:
The patent uses intermediaries by selecting specific non-essential genes as intermediary targets for mutation. These genes serve as mediators that, when modified, provide a predictable and controllable level of attenuation. The intermediaries (specific gene loci) allow researchers to achieve desired attenuation levels through targeted modifications without having to test complex combinations of multiple gene changes.
3Productivity
If packaging cell lines expressing essential viral proteins are generated, then viral propagation is enabled, but the cell lines are challenging to generate due to toxicity of viral proteins
Solution Approach 1:
The patent applies the taking out principle by extracting the essential viral protein expression requirement from the packaging cell line system. Instead of requiring host cells to express toxic essential viral proteins for propagation, the invention provides these essential proteins in trans through external sources (such as complementing cell lines or in vitro systems), allowing the attenuated virus to propagate without the host cells needing to generate packaging cell lines, thereby eliminating the manufacturing difficulty.
4Reliability
If mutations are made in non-essential genes to preserve viral propagation ability, then replication competence is maintained, but further modulation of attenuation requires identification of additional non-essential genes
Solution Approach 1:
The patent applies universality by providing a comprehensive list of multiple non-essential genes that can serve as interchangeable targets for attenuation. Instead of requiring identification of new genes for each attenuation level, the invention offers a universal set of validated gene targets (TK, HA, and other non-essential genes) that can be selectively modified to achieve different degrees of attenuation while all maintaining viral replication competence, simplifying the modulation process.
Data Source
AI summary
Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.